Mirum executive exercises options for 16,988 shares

Mirum Pharmaceuticals President and COO Peter Radovich exercised stock options to acquire 16,988 shares of common stock at $19.19 per share.

Rhea-AI Filing Summary

Mirum Pharmaceuticals President and COO Peter Radovich exercised stock options to acquire 16,988 shares of common stock at $19.19 per share. These options were fully vested at the time of exercise. After the transaction, he directly holds 57,260 shares of Mirum common stock.

Following the exercise, Radovich still holds 48,012 stock options with an exercise price of $19.19 per share, expiring on January 6, 2031. The filing reflects a derivative exercise only, with no open-market share sales reported in this transaction.

Insider Trade Summary

16,988 shares exercised/converted

Exercise 2 txns

Insider Radovich Peter

Role PRESIDENT AND COO

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	16,988	$0.00	$0.00
Exercise	Common Stock	16,988	$19.19	$326K

Holdings After Transaction: Stock Option (right to buy) — 48,012 contracts (Direct); Common Stock — 57,260 shares (Direct)

Footnotes (1)

1. F1. The stock option is fully vested.

Key Figures

Options exercised: 16,988 shares Exercise price: $19.19/share Shares owned after: 57,260 shares +2 more

5 metrics

Options exercised 16,988 shares Common stock acquired via option exercise at $19.19 on June 5, 2026

Exercise price $19.19/share Strike price for exercised stock options

Shares owned after 57,260 shares Direct Mirum common stock holdings after transaction

Options remaining 48,012 options Remaining stock options after exercise, strike $19.19, expire January 6, 2031

Transaction type Code M Exercise or conversion of derivative security (Form 4)

Key Terms

Form 4, stock option, derivative exercise, exercise price, +1 more

5 terms

Form 4 regulatory

"What did Mirum Pharmaceuticals (MIRM) executive Peter Radovich report in this Form 4?"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

stock option financial

"Peter Radovich reported exercising stock options for 16,988 Mirum shares at $19.19 each."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

derivative exercise financial

"The filing reflects a derivative exercise only, with no open-market share sales reported."

exercise price financial

"The $19.19 figure is the exercise price of Radovich’s stock options, not a market trade price."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

fully vested financial

"These options were fully vested at the time of exercise."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Mirum Pharmaceuticals (MIRM) executive Peter Radovich report in this Form 4?

Peter Radovich reported exercising stock options for 16,988 Mirum shares at $19.19 each. This derivative exercise increased his direct common stock holdings to 57,260 shares, with no open-market sales disclosed in the reported transactions.

Did Mirum’s Peter Radovich sell any MIRM shares in this Form 4 filing?

No, the filing shows only an option exercise, with no reported stock sales. Radovich converted 16,988 vested options into common shares at $19.19 per share, increasing his direct share ownership in Mirum Pharmaceuticals.

How many Mirum Pharmaceuticals (MIRM) shares does Peter Radovich hold after the transaction?

After the reported option exercise, Peter Radovich directly holds 57,260 shares of Mirum common stock. This reflects the addition of 16,988 shares acquired through exercising fully vested stock options at $19.19 per share.

What stock options remain for Mirum’s Peter Radovich after this Form 4 event?

Following the exercise, Radovich retains 48,012 stock options with a $19.19 exercise price. These options relate to Mirum common stock and are scheduled to expire on January 6, 2031, according to the filing details.

What is the significance of the $19.19 price in the Mirum (MIRM) Form 4 filing?

The $19.19 figure is the exercise price of Radovich’s stock options, not a market trade price. He used that price to convert 16,988 options into Mirum common shares, as reported in the Form 4 transaction details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 04:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Radovich Peter

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		M		16,988	A	$19.19	57,260	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$19.19	06/05/2026		M			16,988	(1)	01/06/2031	Common Stock	16,988	$0	48,012	D

Explanation of Responses:

1. The stock option is fully vested.

	/s/ Judit Ryvkin, Attorney-in-Fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)